Key Takeaways
- Muted quarter, growth expected: Total income improved YoY but management "expected far better"; EBITDA margins were flat at 13.1% as cost pressures persisted, though gross margins jumped to 46.1% on mix shift.
- CMS is the growth engine, but it is lumpy: CMS clocked ~₹69 crores, over 50% YoY growth, yet sequential inconsistency over the last 4-5 quarters shows the business is still in an early, pre-commercialization phase where development revenues swing quarter to quarter.
- Prime segment dragged by its largest product: The biggest prime product, Levetiracetam, saw a 15% volume decline from demand reduction and customer inventory buildup, pulling down the entire segment.
- Gross margin story is working, operating leverage is not: A favorable mix shift toward CMS and specialty GDS lifted gross margins, but EBITDA margins stayed flat because overall revenues have not yet crossed the threshold where fixed operating costs leverage out.
- What to watch next quarter: Whether Levetiracetam volumes recover as expected, whether the three newly commercialized CMS molecules begin to scale, and whether raw material price softening actually flows through to margins.
CMS Business: The Core Growth Thesis
- Dual structure drives volatility: CMS comprises a baseline commercial business, still small and driven by one key molecule, plus a lumpy development business where revenues depend on which quarter projects are executed. Management asks investors to judge progression over a 15-20 quarter window, not quarter to quarter.
- Pipeline is converting, slowly: Three projects moved from development to commercial over the last year: two are NCEs where Neuland is part of the NDA/filings, and one is a custom-developed molecule for a customer now commercialized with their own customers. Volumes typically start low, pick up after 1-2 years, and peak in years 3-5.
- Delays are real but contained: CMS projects face delays from technical complexities in scaling up phase 3 molecules, sometimes requiring campaigns to pause and return to the lab. Management says these delays do not impact customer timelines because Neuland aligns with customer priorities.
- Customer base is concentrated in biotech: Almost all CMS business comes from small pharma and biotech companies, typically NASDAQ-listed firms with $1-2 billion market caps and one or two products. This concentration means individual customer decisions can swing revenues materially.
- Unit III is the scaling vehicle: Important late-stage CMS projects are being ramped up at Unit III, which is expected to break even in FY23. The unit has significant capacity headroom for at least the next two years.
Saharsh Davuluri: "I think the way I would look at it or rather explain it is our CMS business comprises of both a baseline business as well as a development business. Today, Neuland is a kind of in a phase where are we are moving from development projects and we are moving our development projects into commercial projects."
Prime & GDS: The Drag
- Levetiracetam is the problem in Prime: The largest prime product saw a 15% volume decline from a combination of demand reduction and inventory buildup at customers. Management believes and hopes the decline is temporary, citing historical patterns, and expects to continue gaining market share long-term in what is a large, fragmented 3,000-ton API market where no player holds more than 10% share.
- GDS decline was timing, not structural: GDS declined around 7% QoQ primarily due to timing issues with certain customers and products, including inventory issues at customers. No customers were lost.
- Specialty GDS held up: Products like Donepezil, Salmeterol, Apixaban and Paliperidone did well and helped maintain healthy gross margins, partially offsetting the Prime weakness.
Sucheth Davuluri: "Aditya, we think that your concern is very similar to our concern as well. ... we got in touch with all our customers, we pulled the data from the market, we analyzed the market share of all the companies out there ... we also got feedback from our customers whether they have any accumulated inventory or have they lost market share."
Margins: Gross Up, Operating Flat
- Gross margin jump is mix-driven: Gross margins improved to 46.1% from 41.5% QoQ and 42.4% YoY because of a favorable business mix, with more contribution from higher-margin CMS relative to GDS. This portfolio shift is expected to continue.
- EBITDA margin stuck at 13.1%: Flat YoY because increased cost structures across the whole value chain (raw materials, logistics, power and fuel) and higher operating expenses from Unit III commercialization ate up the gross margin gain.
- Operating leverage is the unlock: EBITDA and PBT margins did not improve because overall revenues have not yet reached a critical threshold. If growth returns in FY23, operating leverage should ensure much better profit margins since operating expenses are likely to be similar across quarters.
- Employee costs rose modestly: The ~₹3 crore sequential increase in employee expenses was mainly from performance-linked increments and a small headcount addition, with bonus apportioned evenly over 12 months.
- Raw material prices softening: Management expects 20% to 25% softening of raw material prices for the full year compared to the beginning of the year, though the Russia-Ukraine conflict continues to cause volatility in pricing but not supply.
Balance Sheet & Cash Flow
- Net debt fell meaningfully: Net debt dropped from ₹212 crore to ₹160 crore because of better cash flow from higher debtor realizations and advances received from customers for certain CMS projects.
- Inventory stays high by design: Management continues to maintain high levels of inventory to avoid any future possible disruption from global supply chain issues.
- No capital raise or M&A planned: Existing facilities are adequate for the next couple of years, and Unit III has significant capacity headroom. No fundraising or acquisition plans as of now.
Pipeline & Business Development
- Early-stage CMS projects added: Three new projects in early stages were added during the quarter, and interesting Phase 2 and Phase 3 molecules from innovator companies have been added over the last six months, facilitated by customer visits to facilities.
- Investment in BD rising: Neuland is adding resources and spending more on B2B marketing to strengthen the CMS pipeline, which management says has already started improving in the last six months.
- CMS growth expected to outpace the company: Management expects CMS to grow at a higher rate than the overall organization's average growth rate, though it declined to provide specific targets or guidance.
Saharsh Davuluri: "If you look at it from a quarter to quarter basis, it does show inconsistency, but the way I would look at our CMS business is look at it from a fairly long perspective, look at it over a 15 quarter period and if you look at it over a 15-20 quarter period, you would actually see that there is progression..."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Levetiracetam volume recovery | Volumes expected to recover based on historical patterns | Coming quarters |
| Unit III breakeven | Unit III expected to break even | FY23 |
| Raw material price softening | 20% to 25% softening vs beginning of year | Full year FY23 |
| CMS molecules commercialized | More molecules to be commercialized | Next 12 months |
| Capacity adequacy | Existing facilities adequate, Unit III has headroom | At least next 2 years |
| Growth resumption | Break away from stagnation period, get back on growth track | FY23 |
| Operating leverage benefit | If growth returns, much better EBITDA and PBT margins expected | FY23 (conditional on growth) |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Total income | ₹221.7 cr, vs ₹202.9 cr in Q1 FY22 |
| EBITDA | ₹29 cr, with margins of 13.1%, flat YoY (13.6% in Q1 FY22), down 220 bps QoQ |
| Gross margin | 46.1%, vs 41.5% in Q4 FY22 and 42.4% in Q1 FY22 |
| Profit after tax | ₹9.8 cr, vs ₹8.6 cr in Q1 FY22 |
| EPS | ₹7.7 |
| CMS revenue | ~₹69 cr, over 50% growth YoY |
| CMS new projects added | 3 new projects in early stages during the quarter |
| CMS share of overall revenue | Over 30% |
| Net debt | ₹160 cr, reduced from ₹212 cr QoQ; over ₹45-50 cr debt repaid in the quarter |
| Unit III remaining block to be depreciated | ~₹225 cr as of June end |
| Unit III annual operating expenses | ~₹60 cr (last year) |
| CAPEX in Q1 | ₹15 cr, of which Unit III was ~₹2 cr |
| Full-year FY23 CAPEX plan | ₹70-80 cr |
| Raw material price impact estimated for full year | ~₹45 cr, based on spot prices |
| Expected raw material price softening for full year | 20-25% compared to beginning of the year |
| Levetiracetam volume decline | 15% decline in volumes |